Dolutegravir

3Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-lineMonographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary,Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The February 2014 monograph topics are sofosbuvir, simeprevir capsules, ibrutinib, hydrocodone extended-release capsules, and eslicarbazepine. The DUE/MUE is on sofosbuvir. © 2014 Thomas Land Publishers, Inc.

Cite

CITATION STYLE

APA

Cada, D., Levien, T., & Baker, D. (2014). Dolutegravir. Hospital Pharmacy, 49(2), 184–195. https://doi.org/10.1310/hpj4902-184

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free